TY - JOUR T1 - 在改善纤维化肺病生活质量动态氧的成本 - 效果：从AmbOx试用JF初步证据 - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.01157-2019 VL - 55 - 2SP - 1901157 AU - 屈，詹妮弗A. AU - 兰珍妮AU - VISCA，迪娜AU - Tsipouri，维斯AU - 森，莱蒂齐亚AU - 斯宾塞，丽莎AU - Adamali，Huzaifa AU - 马赫，托比M. AU - 霍普金森尼古拉斯S. AU - Birring，Surinder S. AU - 夸尔，莫拉格AU - 井，阿索尔U. AU - Sestini，Piersante AU - Renzoni，伊丽莎白A. Y1 - 2020年2月1日UR - HTTP：// ERJ。ersjournals.com/content/55/2/1901157.abstract N2 - 纤维化肺间质疾病（的ILD）是慢性的，并导致发病率，生命的健康相关的质量（的HRQoL），和卫生系统成本的显着影响，通常为渐进性的条件。在例行的日常活动中使用动态氧（AO）可能导致改善运动性能，减少症状和改善流动性在日常生活中。A UK prospective, multicentre, mixed method, randomised controlled crossover trial in patients with fibrotic ILD (AmbOx trial: NCT02286063), the first study on AO effects in daily life, reported improved HRQoL after 2 weeks of AO compared to no intervention, when measured by the King's Brief ILD (K-BILD) questionnaire [1–3]. Although AO is used in ILD, evidence supporting its health-economic impact is absent. Here, we evaluate the cost-effectiveness of AO in patients with ILD, using data collected alongside the AmbOx Trial.Ambulatory oxygen may be cost-effective in improving quality of life in fibrotic lung disease. To be more conclusive, we need to understand societal willingness to pay for quality of life improvements and whether improvements are sustained. http://bit.ly/2pAiBJiThe study was supported by the NIHR Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Members of the DMC: Joanna Porter, Chair; Sunita Rehal, independent statistician; John S. Wort. Members of the TSC: Stephen Durham, Vicky Tsipouri, Ira Jakupovic, Elisabetta Renzoni, Dina Visca, Voon Ong, Arnab Datta. We thank John Tayu Lee for providing input into the design of the economic evaluation component of the study. We also thank the RBH Research and Finance Office for their help in organising and supporting the infrastructure needed for the study, in particular Patrick Petterson and Alla Kashif. The AmbOx study is funded in full by the Research for Patient Benefit Programme National Institute for Health Research (Ref: PB-PG-0712-28073). Additional infrastructure support for the study is being provided by the Royal Brompton NIHR-funded Biomedical Research Unit. ER -